HCA Healthcare (HCA) Stock Forecast & Price Target

$376.62

+1.31 (+0.35%)

(As of 08/21/2024 ET)

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 19 Analyst Ratings

Based on 19 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 4 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for HCA.

Consensus Price Target

$354.67
-5.83% Downside

High Forecast	$438.00
Average Forecast	$354.67
Low Forecast	$271.00

According to the 19 analysts' twelve-month price targets for HCA Healthcare, the average price target is $354.67. The highest price target for HCA is $438.00, while the lowest price target for HCA is $271.00. The average price target represents a forecasted downside of -5.83% from the current price of $376.62.

Type	Current Forecast 8/23/23 to 8/22/24	1 Month Ago 7/24/23 to 7/23/24	3 Months Ago 5/25/23 to 5/24/24	1 Year Ago 8/23/22 to 8/23/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	14 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$354.67	$327.06	$317.00	$310.36
Forecasted Upside	-5.83% Downside	11.63% Upside	11.00% Upside	14.90% Upside

Get HCA Healthcare Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HCA and its competitors with MarketBeat's FREE daily newsletter.

Ad Colonial Metals

Wanted Dead: Petrodollar

The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.

In answer to this issue, we have released a Special Report to the public.

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.84	2.75	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-5.83% Downside	5,586.08% Upside	8.75% Upside
News Sentiment Rating	Neutral News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/19/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$392.00 ➝ $392.00	+4.40%
8/19/2024	Truist Financial 1 of 5 stars		Boost Target	Buy ➝ Buy	$390.00 ➝ $430.00	+15.30%
8/14/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$405.00 ➝ $438.00	+18.74%
7/30/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$315.00 ➝ $365.00	+1.75%
7/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$376.00 ➝ $396.00	+16.14%
7/24/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$329.00 ➝ $378.00	+10.86%
Get the Latest News and Ratings for HCA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for HCA Healthcare and its competitors with MarketBeat's FREE daily newsletter.
7/24/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$367.00 ➝ $396.00	+16.32%
7/24/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$345.00 ➝ $390.00	+14.78%
6/28/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$359.00 ➝ $375.00	+14.85%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$327.00 ➝ $332.00	-0.86%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$396.00	+21.88%
4/30/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$371.00 ➝ $360.00	+16.04%
1/31/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$300.00 ➝ $330.00	+9.45%
1/4/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$277.00 ➝ $301.00	+9.85%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$271.00	+5.23%
11/10/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$280.00	+20.26%
10/25/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$325.00 ➝ $275.00	+21.19%
10/25/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$324.00 ➝ $279.00	+22.87%
7/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$311.00 ➝ $316.00	+14.31%
6/28/2023	1-800-FLOWERS.COM Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/10/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $310.00	+13.12%
4/24/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $350.00	+23.24%
4/24/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $320.00	+13.79%
4/24/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$294.00 ➝ $323.00	+14.86%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$238.00 ➝ $292.00	+14.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:59 AM ET.

HCA Forecast - Frequently Asked Questions

What is HCA Healthcare's forecast for 2024?: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $354.67, with a high forecast of $438.00 and a low forecast of $271.00.
Should I buy or sell HCA Healthcare stock right now?: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last twelve months. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCA shares.
Does HCA Healthcare's stock price have much upside?: According to analysts, HCA Healthcare's stock has a predicted upside of 12.90% based on their 12-month stock forecasts.
Has HCA Healthcare been upgraded by Wall Street analysts recently?: Over the previous 90 days, HCA Healthcare's stock had 1 upgrade by analysts.
What analysts cover HCA Healthcare?: HCA Healthcare has been rated by research analysts at Baird R W, Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Oppenheimer, Robert W. Baird, Royal Bank of Canada, SVB Leerink, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like HCA Healthcare more than its competitors?: Analysts like HCA Healthcare more than other "medical" companies. The consensus rating score for HCA Healthcare is 2.84 while the average consensus rating score for "medical" companies is 2.75. Learn more on how HCA compares to other companies.